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Abstract
Background: Insulin-like growth factor binding protein (IGFBPs) have been as potential tumor
suppressors in the occurrence and development of tumors. Cellular Fas-associated death domain-
like interleukin-1β-converting enzyme (FLICE)-like inhibitory protein (cFLIP) contains a death effect
domain (DED), which blocks death receptor pathway and inhibits apoptosis.
Methods: We collected normal cervical tissues from 28 subjects, CIN samples from 37 patients,
and cervical cancer tissues from 40 patients. In these samples, we then measured the expression
levels of IGFBP-5 and cFLIP via RT-PCR and immunohistochemistry, and we detected the presence
of high-risk HPV by Hybrid capture II assays in cervical secretions provided by the subjects.
Results: significant differences in the expression of IGFBP-5 protein among the normal, CIN, and
CC tissues (P < 0.05). The highest expression of IGFBP-5 protein was found in CIN stage II and III
tissues, whereas the expression of IGFBP-5 in CC samples was decreased relative to controls. The
expression level was affected by factors such as clinical stage, pathological differentiation, and lymph
node metastasis. Relative to the controls, IGFBP-5 mRNA content was higher in the CC group and
lower in the CIN group (P < 0.05). No expression of cFLIP protein or mRNA was detected in
normal cervical tissues. However, the degree of pathological changes correlated with increasing
expression of cFLIP protein and mRNA, and significant differences were therefore detected
between groups (P < 0.05). The HPV infection rates in the CIN and CC groups were much higher
than in the normal group (P < 0.05).
Conclusion: IGFBP-5 expression is up-regulated in response to progression of CIN and down-
regulated in invasive cervical carcinoma. Detection of IGFBP-5 and cFLIP expression levels, may
prove particularly useful for diagnosing and differentiating CIN and CC.
Background
Cervical carcinoma (CC) is a common cancer of the
female reproductive system. Recently, however, the inci-
dence of cervical intraepithelial neoplasia (CIN) has been
rising. Development of CIN and CC from normal cervical
tissue is a gradual process, though the occurrence and
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development of these diseases are directly associated with
persistent human papilloma virus (HPV) infections. There
can be a 10- to 20-year latency between HPV infection and
development of cervical carcinoma, and only high-risk
HPV infections are not sufficient to induce cellular trans-
formation and tumor occurrence.
Insulin growth factor binding protein 5 (IGFBP-5) is a
secreted protein that can bind to insulin-like growth fac-
tors, and it can regulate cell growth, differentiation, apop-
tosis, adherence, and movement. IGFBP-5 has also been
shown to play an important role in regulating tumor
growth. Cellular Fas-associated death domain-like inter-
leukin-1β-converting enzyme (FLICE)-like inhibitory pro-
tein (cFLIP) can block the death receptor pathway, which
has the effect of inhibiting apoptosis. In the present study,
immunohistochemistry and semi-quantitative RT-PCR
were applied to measure the expression levels of IGFBP-5
and cFLIP in normal cervical tissues as well as CIN and CC
tissues. This analysis allowed us to assess the potential
clinical significance of these proteins to diagnose and dif-
ferentiate CIN and CC.
Methods
Research subjects and grouping
Seventy-seven CIN and CC specimens were surgically
removed at the Qi Lu Hospital of Shangdong University
between July 2006 and April 2007. Patients included in
this study were aged 30 to 82, with an average age of 41
years old. Thirty-seven subjects were diagnosed with dif-
ferent stages of CIN, including 11 cases of CIN stage I, 13
cases of CIN stage II, and 13 cases of CIN stage III. Clinical
staging of cervical squamous cell carcinomas was per-
formed according to the Federation International of
Gynecology and Obstetrics (FIGO). The CC specimens
were classified as stage I (26) or stage II (14). The degrees
of tumor differentiation were verified by postoperative
pathology, and these included 24 cases of well-differenti-
ated CC and 16 cases of moderately or poorly differenti-
ated CC. Twenty-eight normal cervical tissues were
collected to serve as controls. All HE staining sections were
rechecked and confirmed by pathology experts, and no
patients had been given radiotherapy or chemotherapy.
Reagents and instruments
Primary antibodies used in this study include IGFBP-5
rabbit anti-human polyclonal antibody (Boster Co., Ltd.,
Wuhan) and cFLIP rabbit anti-human polyclonal anti-
body (American Neomarker Co.). The DAB kit (Boster
Co., Ltd., Wuhan) was used to reveal positive staining. The
Olympus IX81 electric research system inverted micro-
scope was used to examine the sections, and the Hybrid
Capture II system (American DIGENE Co.) was used to
detect high-risk HPV. Reagents used for RNA extraction
and RT-PCR include Trizol, DNA marker (TaKaRa Co.), a
reverse transcriptase kit, and a PCR kit (PROMEGA Co.).
Specimen handling
Tissue samples were drawn from all the specimens after a
brief period of culture (20 min) and stored in liquid nitro-
gen. Additionally, parts of each specimen were fixed in
10% neutral formalin and embedded in paraffin wax.
Four serial sections (3–4 mm) were cut from each paraffin
block. Cervical secretions from the external cervical orifice
and cervical cavity were collected by cervical brush, which
was kept in a vial containing HPV cell storage solution.
The Hybrid capture II assay was directly applied to these
samples to detect high-risk HPV DNA.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted according to the Trizol protocol.
To determine the concentration of the RNA, UV absorb-
ance was measured in a spectrophotometer. cDNA was
synthesized by reverse transcription of 2 μg of total RNA.
PCR amplification of IGFBP-5 and cFLIP was performed
in a final volume of 20 μl, with simultaneous amplifica-
tion of β-actin as an internal reference. The primers were
synthesized by Invitrogen Co., Ltd. (Shanghai). The β-
actin primer sequences were forward, 5'-GTGGG GCGCC
CCAGG CACCA-3' and reverse 5'-GTCCT TAATG TCACG
CACGA TTTC-3', which amplified a band of 540 bp. The
forward primer sequence for IGFBP-5 was 5'-AATTCAAG-
GCTCAGA AGCGA-3', while the reverse primer sequence
was 5'-GGCAG AAACT CTGCT GTTCC-3'. These primers
amplified a 154 bp band. The forward primer sequence
for cFLIP was 5'-CGTGC TGTGT ACCTG CCCAAT-3', and
the reverse primer sequence was 5'-CACTGAAAGTC-
CCCGTCAAC-3' [11]. These primers amplified a 226 bp
band.
PCR products were analyzed by 1.5% agarose gel electro-
phoresis, and they were observed and photographed
under ultraviolet light. Band intensities were analyzed by
the Touching gel imaging system and compared with β-
actin to calculate relative expression levels.
Immunohistochemical method
Tissue samples were stained with two different antibodies
via immunohistochemical method according to conven-
tional staining procedures. Negative and positive controls
were run synchronously. For the positive control, CIN and
CC tissues were replaced by normal cervical tissues, while
for the negative control, phosphate buffer substituted for
the primary antibody. Paraffin sections were deparaffin-
ized by routine methods, and antigen retrieval was
achieved by microwave treatment. After blocking with
serum, IGFBP-5 and cFLIP rabbit anti-human polyclonal
antibodies were applied at a dilution of 1:50 and incu-Journal of Experimental & Clinical Cancer Research 2009, 28:70 http://www.jeccr.com/content/28/1/70
Page 3 of 6
(page number not for citation purposes)
bated overnight at 37°C. The samples were rinsed three
times with PBS (pH 7.2) for 5 min each, then incubated
with biotin-labeled goat anti-rabbit IgG for 15 min at
37°C, rinsed again, and incubated with horseradish per-
oxidase-conjugated streptavidin for 30 min at 37°C.
Finally, the sections were rinsed, stained with DAB, re-
stained by hematoxylin, dehydrated in an ethanol gradi-
ent, cleared in xylene, and fixed by neutral balata.
Immunohistochemical assessment
This semi-quantitative assay was conducted under a high
power lens (×400) integrated with staining intensity and
the percent of positive cells. The expression of IGFBP-5
and cFLIP proteins in the histocytes was mostly localized
to the cytoplasm, which appeared brownish yellow and
contained brownish yellow particles. More than 10 repre-
sentative fields of each section were observed under high
power before we evaluated the staining results. We looked
for positive staining within the squamous epithelia of the
control group, in the CIN focus position of the CIN group,
and in the cancer focus of the CC group. We scored for
staining intensity (0: no color; 1: light yellow; 2: brownish
yellow; 3: chocolate brown) and the percent of positive
cells (0: < 5%; 1: 5 to 25%; 2: 26 to 50%; 3: 51 to 75%; 4:
> 75%) separately, and the summation of the two gave the
final score (-: 0–2; +: 3–4; ++: 5–6; +++: 7) [12].
Detection of high risk-HPV
Hybrid capture II assay was applied to directly detect high
risk-HPV DNA (American DIGENE Co.). Thirteen HPV
subtypes (16/18/31/33/35/39/45/51/52/56/58/59/68)
can be detected by this method. In this protocol, double-
stranded DNA in the specimen is turned into single-
s t r a n d e d  D N A ,  w h i c h  i s  t h e n  c o m b i n e d  w i t h  a n  R N A
probe to form a DNA-RNA hybrid. This hybrid was fixed
with a specific antibody, which was subsequently com-
bined with an enzyme-conjugated secondary antibody.
The samples were then incubated with a substrate that flu-
oresces upon encountering the enzyme, such that HPV
DNA content in the original specimen can be calculated
according to the light intensity signal (RLU). These meas-
ured RLU values from the specimens were then divided by
the RLU value of a positive control (CO). If the ratio
(RLU/CO) of a given specimen was between 0.8 and 1.2,
the specimen was weakly positive, whereas less than 0.8
indicated that the specimen was negative.
Statistical analysis
All of the data were processed by the statistical software
package SPSS10.0 and represented as mean ± standard
deviation (SD). Kruskal-Wallis test for group compari-
sons, as well as the Mann-Whitney U test for nonparamet-
ric independent two-group comparisons were performed.
Differences with P < 0.05 were regarded as statistically sig-
nificant, P < 0.01 as highly statistically significant.
Results
High-risk HPV infection rates
The infection rates of the 13 HPV subtypes in the CIN and
CC groups were all significantly higher than in the control
group (P < 0.05), while there was no significant difference
in the HPV infection rates between the CIN and SCC
groups (P > 0.05) (Table 1).
Expression of IGFBP-5 and cFLIP proteins
The positive staining rate of IGFBP-5 was 71.4% in nor-
mal cervical tissues, 91.9% in CIN samples, and 45.0% in
CC samples. The expression level in the CIN group was
significantly different from others (Kruskal-Wallis test, P <
0.05). There were also significant differences in the expres-
sion of cFLIP among these three groups (Kruskal-Wallis
test, P < 0.01). P < 0.05) (Table 2).
The relationship between IGFBP-5 and cFLIP expression 
and clinicopathological parameters
There were significant differences in IGFBP-5 protein
expression among CIN stage I, II, and III samples. In CC
samples, the degree of positive staining was related to clin-
icopathological stage, lymph node metastasis, and the
degree of cell differentiation (P < 0.05). There were also
significant differences in the level of cFLIP expression
among the CIN stage I, II, and III groups (P < 0.05), and
this expression level was related to pathological differen-
tiation in CC (P < 0.05) (Table 3). Correlation studies
were carried out using the Spearman and Kendall tests.
PCR results
The intensity (gray level) ratios of IGFBP-5/β-actin and
cFLIP/β-actin were determined so as to represent the
expression levels of IGFBP-5 and cFLIP mRNA. Larger
ratios correlated with higher levels of expression of the tar-
get gene. Expression of IGFBP-5 were highest in the CIN
stage II and III groups (1.0500 ± 0.0875), which were
4.94-fold higher than the relative expression levels of the
normal group (0.2124 ± 0.0795) and 2.92-fold higher
than those of the CC group (0.3600 ± 0.0575). The
expression level in the CC group was in turn significantly
Table 1: Infection rate of normal tissue, CIN and Squamous Cell 
Carcinoma
Group n + - Infection Rate(%)
Normal tissue 28 6 22 21.4
CIN 37 30 7 81.1*
Squamous Cell Carcinoma 40 36 4 90.0*
*P < 0.05 vs. controlJournal of Experimental & Clinical Cancer Research 2009, 28:70 http://www.jeccr.com/content/28/1/70
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higher than that of the normal group (P < 0.05) (Fig. 1).
The highest expression of cFLIP mRNA was observed in
the CC group (6.8874 ± 0.6663), which was 2.26-fold
higher than that of the CIN stage II and III groups (3.0426
± 0.0819). The lowest expression level was detected in the
normal group (0.0246 ± 0.0100; P < 0.05) (Fig. 2 and Fig.
3).
Discussion
Insulin-like growth factor (IGF) -I and IGF-II are impor-
tant somatomedins in humans. Rather than moving freely
through the blood and tissue fluids, these proteins bind to
IGFBPs, mainly IGFBPs 1–6. IGFBPs inhibit the activity of
IGF by tightly adhering to the ligand, though some bind-
ing proteins also activate the insulin-like growth factor
[1]. Therefore, IGFBPs have recently received more recog-
nition as potential tumor suppressors in the occurrence
and development of tumors.
IGFBP-5 can inhibit the proliferation of some tumor cells.
It has been reported that the down-regulation of IGFBP-5
correlates with the formation of oral keratinocyte cell
tumors and IGFBP-5 over-expression in renal granular-cell
tumor and fibroblast cell lines [2]. In breast cancer,
IGFBP-5 interacts with various extracellular matrix com-
ponents, and it is regulated by proteolysis and hormones
that act on the mammary gland [3]. Pell et al. reported
insulin-independent spontaneous anti-apoptosis activity
of IGFBP-5 during the course of myogenesis [4]. Another
study also showed that an IGF-independent mechanism
could mediate the effect of IGFBP-5 on osteoprogenitor
cells [5]. IGFBP-5 was also shown to enhance growth inhi-
bition induced by tumor necrosis factor (TNF)-α. In can-
cer cells, IGFBP-5 activated the caspase-8 signal
transduction pathway, increased the structure sensitivity
to TNF-α, and induced the internal apoptosis pathway [6].
According to the results of the present study, with increas-
ing severity of CIN, the expression of IGFBP-5 increased at
both the mRNA and protein levels. We presume that in
intraepithelial neoplasia, the body compensatorily up-
regulates the expression of IGFBP-5, which activates the
caspase-8 signal transduction pathway, increases the
structure sensitivity to TNF-α, induces the internal apop-
tosis pathway, and delays tumor advancement. However,
the expression of IGFBP-5 in the CC group was signifi-
cantly lower than that of the CIN and normal cervical
mucosa groups (P < 0.05). This trend was associated with
clinicopathological stage, lymph node metastasis, and the
degree of cell differentiation such that greater tumor dif-
ferentiation and later clinical stages of CC were linked to
lower levels of IGFBP-5 expression. The reason for this
Table 2: IHC results for IGFBP-5 and cFLIP
Group n IGFBP-5 (+ ~ +++) cFLIP (+ ~ +++)
N% * P 1 **P2 n% * P 1 **P2
Normal tissue 28 20 71.44 6 21.43
CIN I 37 8 72.73 1.0000 1.0000 4 36.37 0.4238 0.4238
CIN II/III 26 26 100.00 0.0045 0.0212 20 76.92 <0.0001 0.0275
Cancer tissue 40 18 45.00 0.0308 <0.0001 33 82.50 <0.0001 0.5778
* P < 0.05 vs. normal tissue, ** P < 0.05 vs. adjacent abnormal tissue
Table 3: The relationship between expression of IGFBP-5 and cFLIP and clinicopathological parameters in CC
clinical parameter n IGFBP5 n cFLIP
- + %P - + %P
Lymph node metastasis
existence 12 10 2 16.67 12 2 10 83.33
Nonexistence 28 12 16 57.14 P < 0.05 28 5 23 82.14 P > 0.05
Clinical stage
Stage I 26 11 15 57.69 26 6 20 72.92
Stage II 14 11 3 21.43 P < 0.05 14 1 13 92.86 P > 0.05
Pathological differentiation
well differentiated 24 6 18 75.00 24 7 17 70.83
moderately or poorly differentiated 16 12 4 25.00 P < 0.05 16 0 16 100.0 P < 0.05
P values represent multiple comparisons within groupsJournal of Experimental & Clinical Cancer Research 2009, 28:70 http://www.jeccr.com/content/28/1/70
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IGFBP down-regulation in CC remains unclear, though it
may be explained by the down-regulation of HPV
encoded proteins or the transcription of IGFBP-5 mRNA.
Irmler et al. [7] were the first group to find that cFLIP con-
tains a death effect domain (DED), which blocks the
death receptor pathway and inhibits apoptosis. The anti-
apoptosis effect of cFLIP has been attributed to block the
formation of death-inducing signaling complexes (DISC),
the activation of caspases-8 and 10 and the course of the
general caspase cascade. These effects are mediated by the
two DEDs in the N-terminus of cFLIP that competitively
bind to FADD and/or caspases-8 and 10. Under physio-
logical conditions, cFLIP may protect normal cells from
apoptosis induced by TRAIL. However, in tumor cells,
over-expression of cFLIP inhibited the activation of the
caspase-8 signal transduction pathway and cell apoptosis
[8]. In traumatic brain injury, diverse mechanisms of
cFLIP regulation could impact the degree of cell mortality
and later programmed cell death [9]. A study demon-
strated that cFLIP expression was also related to high-risk
HPV infection and integration [10-12]. In this study, we
found that the expression of cFLIP was significantly higher
in the CC group than in the normal and CIN groups.
Our results suggest that in CC, decreased expression of
IGFBP-5 might lead intracellular caspase-8 to not be effec-
tively activated. Increased expression of cFLIP may cause
the caspase-8 signal transduction pathway to be inhibited
and stop the cascade reaction such that apoptosis of CC
cells would be inhibited. This effect may block apoptosis
signal transduction pathways induced by Fas, TRAIL, etc.
and in turn promote the proliferation of tumor cells.
In this study, high-risk HPV was also detected. The rate of
HPV infection was significantly greater in the CIN group
than in the healthy control group (P < 0.05), though no
differences were seen between the CIN and CC groups (P
> 0.05). We also screened the hyper lesion of the cervix
correlated with detection of HPV and found that the omis-
sion diagnostic rate was very low.
Conclusion
In summary, IGFBP-5 was highly expressed in CIN, and it
may participate as a tumor suppressor in the occurrence
Expression of IGFBP-5 (154 bp, A-lanes) and β-actin (540 bp,  B-lanes) mRNA Figure 1
Expression of IGFBP-5 (154 bp, A-lanes) and β-actin 
(540 bp, B-lanes) mRNA. M = Marker, A1 = Normal cer-
vical tissues group, A2-5 respectively express CIN I, II, III, 
and cervical squamous cell carcinoma groups.
Expression of cFLIP (226 bp, B-lanes) and β-actin (540 bp, A- lanes) mRNA Figure 2
Expression of cFLIP (226 bp, B-lanes) and β-actin 
(540 bp, A-lanes) mRNA. M = Marker, B1 = Normal cervi-
cal tissues group, B2–5 respectively express CIN I, II, III and 
cervical squamous cell carcinoma groups.
Immunohistochemical detection of IGFBP-5 and cFLIP in  patient tissues Figure 3
Immunohistochemical detection of IGFBP-5 and 
cFLIP in patient tissues. A, Expression of IGFBP-5 in CIN 
I tissue: ++(×400); B, Expression of IGFBP-5 in CIN II tissue: 
+++ (×400); C, Expression of cFLIP in cervical cancer tissue: 
++ (×400). D, Expression of IGFBP-5 in cervical cancer tis-
sue: - (×200).Publish with BioMed Central    and   every 
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and development of cervical lesions. Down-regulation of
IGFBP-5 expression was closely related to CC infiltration,
metastasis, and differentiation, whereas cFLIP was highly
expressed in CC. The interaction of these two effects may
promote the progression of CC. Further study is required
to confirm the roles played by these two proteins in the
development of these diseases. Analysis of IGFBP-5 and
cFLIP expression levels, may be useful tools for clinical
diagnosis and differential diagnosis of CIN and cervical
cancer.
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